open access

Vol 90, No 1 (2019)
ORIGINAL PAPERS Gynecology
Published online: 2019-01-31
Get Citation

Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS)

Marcin Januszewski, Tadeusz Issat, Alicja A Jakimiuk, Malgorzata Santor-Zaczynska, Artur J Jakimiuk
DOI: 10.5603/GP.2019.0002
·
Pubmed: 30756365
·
Ginekol Pol 2019;90(1):7-10.

open access

Vol 90, No 1 (2019)
ORIGINAL PAPERS Gynecology
Published online: 2019-01-31

Abstract

Objectives: To evaluate the effects of a combined Myo-inositol (MI) and D-chiro-inositol (DCI) therapy on the hormonal and metabolic parameters of women with PCOS. Prospective clinical study. Clinical Study registration number — EUPAS25705

Material and methods: Seventy women diagnosed with PCOS according to the Rotterdam criteria were enrolled in this study. Patients received a combined therapy of one tablet that contained 550 mg of inositol (myo-inositol (MI) and D-chiro-inositol (DCI) in a ratio of 10:1) twice a day for 6 months. At each of 3 visits, the body weight, height and BMI were all recorded; and serum levels of free testosterone (fT), sex hormone-binding globulin (SHBG), luteinizing hormone (LH), follicle-stimulating hormone (FSH) and glucose with insulin during standard OGTT (75 g) were measured. Also at each visit, transvaginal ultrasonography and skin condition assessments were performed.

Results: Significant body weight reduction and decreases in fT, FSH, LH and insulin levels, as well as significant increase of serum SHBG concentrations were observed. Serum glucose levels during OGTT decreased after 6 months of treatment. Also, skin conditions improved after only three months of treatment.

Conclusions: Combination of MI and DCI in a ratio 10:1 seems to be efficient in improving both metabolic and hormonal parameters in patients with PCOS.  

Abstract

Objectives: To evaluate the effects of a combined Myo-inositol (MI) and D-chiro-inositol (DCI) therapy on the hormonal and metabolic parameters of women with PCOS. Prospective clinical study. Clinical Study registration number — EUPAS25705

Material and methods: Seventy women diagnosed with PCOS according to the Rotterdam criteria were enrolled in this study. Patients received a combined therapy of one tablet that contained 550 mg of inositol (myo-inositol (MI) and D-chiro-inositol (DCI) in a ratio of 10:1) twice a day for 6 months. At each of 3 visits, the body weight, height and BMI were all recorded; and serum levels of free testosterone (fT), sex hormone-binding globulin (SHBG), luteinizing hormone (LH), follicle-stimulating hormone (FSH) and glucose with insulin during standard OGTT (75 g) were measured. Also at each visit, transvaginal ultrasonography and skin condition assessments were performed.

Results: Significant body weight reduction and decreases in fT, FSH, LH and insulin levels, as well as significant increase of serum SHBG concentrations were observed. Serum glucose levels during OGTT decreased after 6 months of treatment. Also, skin conditions improved after only three months of treatment.

Conclusions: Combination of MI and DCI in a ratio 10:1 seems to be efficient in improving both metabolic and hormonal parameters in patients with PCOS.  

Get Citation

Keywords

inositol; PCOS; OGTT; MI DCI ratio

About this article
Title

Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS)

Journal

Ginekologia Polska

Issue

Vol 90, No 1 (2019)

Pages

7-10

Published online

2019-01-31

DOI

10.5603/GP.2019.0002

Pubmed

30756365

Bibliographic record

Ginekol Pol 2019;90(1):7-10.

Keywords

inositol
PCOS
OGTT
MI DCI ratio

Authors

Marcin Januszewski
Tadeusz Issat
Alicja A Jakimiuk
Malgorzata Santor-Zaczynska
Artur J Jakimiuk

References (27)
  1. Knochenhauer ES. Prevalence of the Polycystic Ovary Syndrome in Unselected Black and White Women of the Southeastern United States: A Prospective Study. Journal of Clinical Endocrinology & Metabolism. 1998; 83(9): 3078–3082.
  2. Brusco GF, Mariani M. Inositol: effects on oocyte quality in patients undergoing ICSI. An open study. Eur Rev Med Pharmacol Sci. 2013; 17(22): 3095–3102.
  3. Colazingari S, Treglia M, Najjar R, et al. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet. 2013; 288(6): 1405–1411.
  4. Helvaci N, Karabulut E, Demir AU, et al. Polycystic ovary syndrome and the risk of obstructive sleep apnea: a meta-analysis and review of the literature. Endocr Connect. 2017; 6(7): 437–445.
  5. Dinicola S, Chiu T, Unfer V, et al. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome. The Journal of Clinical Pharmacology. 2014; 54(10): 1079–1092.
  6. Hamid AA, Madkour WI, Borg T. Inositol versus Metformin administration in polycystic ovary syndrome patients. Evidence Based Womenʼs Health Journal. 2015; 5(3): 93–98.
  7. Bevilacqua A, Carlomagno G, Gerli S, et al. Results from the International Consensus Conference on myo-inositol and D-chiro-inositol in Obstetrics and Gynecology--assisted reproduction technology. Gynecol Endocrinol. 2015; 31(6): 441–446.
  8. Artini PG, Di Berardino OM, Papini F, et al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol. 2013; 29(4): 375–379.
  9. Carlomagno G. Contribution of myo-inositol and melatonin to human reproduction. Eur J Obstet Gynecol Reprod Biol. 2011; 159(2): 267–272.
  10. Bevilacqua A, Carlomagno G, Gerli S, et al. Results from the International Consensus Conference on myo-inositol and D-chiro-inositol in Obstetrics and Gynecology--assisted reproduction technology. Gynecol Endocrinol. 2015; 31(6): 441–446.
  11. Minozzi M, Nordio M, Pajalich R. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci. 2013; 17(4): 537–540.
  12. Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci. 2012; 16(5): 575–581.
  13. Jakimiuk A, Szamatowicz J. Rola niedoboru inozytolu w patofizjologii zaburzeńwystępujących w zespole policystycznych jajników. Ginekol Pol. 2014; 85: 54–57.
  14. Isabella R, Raffone E, Isabella R, et al. CONCERN: Does ovary need D-chiro-inositol? J Ovarian Res. 2012; 5(1): 14.
  15. Lee JY, Kim Yr, Park J, et al. Inositol polyphosphate multikinase signaling in the regulation of metabolism. Ann N Y Acad Sci. 2012; 1271: 68–74.
  16. Carlomagno G, Unfer V. Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci. 2011; 15(8): 931–936.
  17. Unfer V, Porcaro G. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome. Expert Rev Clin Pharmacol. 2014; 7(5): 623–631.
  18. Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999; 340(17): 1314–1320.
  19. Papaleo E, Unfer V, Baillargeon JP, et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol. 2007; 23(12): 700–703.
  20. Sortino MA, Salomone S, Carruba MO, et al. Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols. Front Pharmacol. 2017; 8: 341.
  21. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012; 33(6): 981–1030.
  22. Dunaif A, Segal KR, Futterweit W, et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989; 38(9): 1165–1174.
  23. Genazzani AD, Lanzoni C, Ricchieri F, et al. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol. 2008; 24(3): 139–144.
  24. Dinicola S. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome. Trial. Obstet Gynecol. 2015 Aug. ; 126(2): 310–5.
  25. Larner J. D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res. 2002; 3(1): 47–60.
  26. Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE, et al. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care. 2006; 29(2): 300–305.
  27. Costantino D, Minozzi G, Minozzi E, et al. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009; 13(2): 105–110.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl